TG4001 can induce de novo immune responses against HPV16 E6 and E7 antigens in patients with HPV16-positive anogenital cancers
Patients with a complete clinical response also have strong immunoreactivity induced by the therapeutic vaccine
Transgene is preparing a clinical trial for registration
Strasbourg, France, June 5, 2023, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops viral immunotherapies for the treatment of cancer, announces the presentation of new data on TG4001. These data confirm the ability of this innovative therapeutic vaccine candidate to induce immune responses against HPV16 antigens, which are associated with antitumor responses. These results were presented in a poster at the annual meeting of the American Society of Clinical Oncology (ASCO 2023), in Chicago (USA).
…/…